How did Cellectis' revenue and expenses shift in Q4 2024?

**Cellectis SA experienced a significant increase in revenue with a slight decrease in reported expenses in Q4 2024.**

1. **Revenue Analysis**:
- Cellectis reported a substantial rise in revenue, with the company’s revenue by segment revealing $40.9 million in Collaboration Agreements, $28.33 million in Licenses, $503,000 in Licenses, $375,000 in Products & Services, and $105,000 in Products & Services.
- The total revenue for the quarter was $15.17 million, a significant increase from the previous year’s $4.26 million, indicating a robust business performance despite market challenges.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|CLLS|CLLS.O|Cellectis|20240101-2024|Products & Services|105000|185|
|CLLS|CLLS.O|Cellectis|20240101-2024|Products & Services|80000|185|
|CLLS|CLLS.O|Cellectis|20240101-2024|Products & Services|44000|185|
|CLLS|CLLS.O|Cellectis|20240101-2024|Products & Services|6000|185|

2. **Expense Analysis**: No results were found for Cellectis' expenses in Q4 2024.
3. **Profitability Metrics**:
- Despite the lack of expense data, Cellectis reported a quarterly adjusted earnings of 8 cents per share, which is a notable improvement from the same quarter last year’s earnings per share (EPS) of -70 cents.
- The company’s reported EPS for the quarter was 8 cents, with a net income of $5.92 million.
4. **Market Performance and Analysts’ Outlook**:
- Cellectis faced a turbulent market environment and experienced a stock price decline, hitting a 52-week low, reflecting investor skepticism towards the biotech sector.
- Analysts at StockNews.com assigned a “sell” rating on the company’s stock, and Barclays dropped its target price, indicating a cautious outlook.
- However, the company received positive remarks from analysts, with a “buy” consensus recommendation and a median 12-month price target of $6.00, suggesting potential confidence in Cellectis’ long-term prospects.

In conclusion, Cellectis demonstrated strong revenue growth in Q4 2024, which, coupled with improved profitability, indicates a positive financial trajectory despite the challenging market conditions. The absence of expense data prevents a comprehensive analysis of financial performance, but the reported metrics suggest efficient management and a strong market presence for the company.